Randy S D'Amico1, Michael B Cloney2, Adam M Sonabend3, Brad Zacharia3, Matthew N Nazarian4, Fabio M Iwamoto5, Michael B Sisti3, Jeffrey N Bruce1, Guy M McKhann3. 1. Gabriele Bartoli Brain Tumor Research Laboratory, Columbia University College of Physicians and Surgeons, New York, New York, USA; Department of Neurological Surgery, Columbia University Medical Center, New York, New York, USA. 2. Gabriele Bartoli Brain Tumor Research Laboratory, Columbia University College of Physicians and Surgeons, New York, New York, USA. Electronic address: mbc2121@cumc.columbia.edu. 3. Department of Neurological Surgery, Columbia University Medical Center, New York, New York, USA. 4. Gabriele Bartoli Brain Tumor Research Laboratory, Columbia University College of Physicians and Surgeons, New York, New York, USA. 5. Department of Neurology, Columbia University Medical Center, New York, New York, USA.
Abstract
BACKGROUND: Glioblastoma (GBM) occurs more commonly in elderly patients. However, these patients are often excluded from clinical trials. The absence of solid evidence has resulted in a nihilistic view of GBM in the elderly and a traditionally conservative treatment approach. In particular, the safety of surgical resection for both primary and recurrent GBM is poorly understood in elderly patients. METHODS: In a retrospective cohort of patients aged ≥65 years, we examined selection for biopsy, surgical resection, and reoperation for recurrent disease. We also analyzed complication rates after initial resection and reoperation for recurrent disease. We identified 319 elderly patients with pathologically proven GBM who underwent a total of 274 craniotomies at our institution between 2000 and 2012. Events were reported according to the methods used in the Glioma Outcomes Project. RESULTS: The overall rate of complications after resection was 21.9%, with a rate of neurological complications of 7.7%. The rates of neurological, regional, and systemic complications were not significantly different after initial craniotomy and reoperation for GBM in elderly patients. Reoperations were not associated with an increased risk of complications. Low cardiovascular risk, improved functional status, and hemispheric GBM were associated with selection for more aggressive surgical treatment. Younger age and improved functional status were associated with a reduced likelihood of complications. CONCLUSIONS: We conclude that in select patients, age alone should not preclude the decision to pursue aggressive surgical management.
BACKGROUND:Glioblastoma (GBM) occurs more commonly in elderly patients. However, these patients are often excluded from clinical trials. The absence of solid evidence has resulted in a nihilistic view of GBM in the elderly and a traditionally conservative treatment approach. In particular, the safety of surgical resection for both primary and recurrent GBM is poorly understood in elderly patients. METHODS: In a retrospective cohort of patients aged ≥65 years, we examined selection for biopsy, surgical resection, and reoperation for recurrent disease. We also analyzed complication rates after initial resection and reoperation for recurrent disease. We identified 319 elderly patients with pathologically proven GBM who underwent a total of 274 craniotomies at our institution between 2000 and 2012. Events were reported according to the methods used in the Glioma Outcomes Project. RESULTS: The overall rate of complications after resection was 21.9%, with a rate of neurological complications of 7.7%. The rates of neurological, regional, and systemic complications were not significantly different after initial craniotomy and reoperation for GBM in elderly patients. Reoperations were not associated with an increased risk of complications. Low cardiovascular risk, improved functional status, and hemispheric GBM were associated with selection for more aggressive surgical treatment. Younger age and improved functional status were associated with a reduced likelihood of complications. CONCLUSIONS: We conclude that in select patients, age alone should not preclude the decision to pursue aggressive surgical management.
Authors: Stephanie G Kellermann; Christina A Hamisch; Daniel Rueß; Tobias Blau; Roland Goldbrunner; Harald Treuer; Stefan J Grau; Maximilian I Ruge Journal: J Neurooncol Date: 2017-06-21 Impact factor: 4.130
Authors: Brett E Youngerman; Alfred I Neugut; Jingyan Yang; Dawn L Hershman; Jason D Wright; Jeffrey N Bruce Journal: J Neurooncol Date: 2017-11-14 Impact factor: 4.130
Authors: Andrea Di Cristofori; Barbara Zarino; Claudia Fanizzi; Giorgia Abete Fornara; Giulio Bertani; Paolo Rampini; Giorgio Carrabba; Manuela Caroli Journal: J Neurooncol Date: 2017-07-06 Impact factor: 4.130
Authors: Michael Brendan Cloney; Adam M Sonabend; Jonathan Yun; Jingyan Yang; Fabio Iwamoto; Suprit Singh; Govind Bhagat; Peter Canoll; George Zanazzi; Jeffrey N Bruce; Michael Sisti; Sameer Sheth; E Sander Connolly; Guy McKhann Journal: J Neurooncol Date: 2017-01-23 Impact factor: 4.130